RECRUITING

EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations

Talk to us

Conditions

Lung CancerEGFR Gene MutationEGFR-related lung cancerEGFR positive lung cancer

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This research study is studying a new blood test to screen for Epidermal Growth Factor Receptor (EGFR) positive lung cancer in healthy individuals at risk for the disease and who cannot undergo regular lung cancer screening. The name of the test used in this research study is: -Circulating free DNA (cfDNA) Assay

Official Title

EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations

Quick Facts

Study Start:2025-04-01
Study Completion:2027-12-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06716580

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:40 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Narjust Florez, MD
CONTACT
617-582-7335
narjust_florez@dfic.harvard.edu

Principal Investigator

Narjust Florez, MD
PRINCIPAL_INVESTIGATOR
Dana-Farber Cancer Institute

Study Locations (Sites)

Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
United States
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
United States
Massachusetts General Hospital
Boston, Massachusetts, 02215
United States
Dana-Farber Cancer Institute at Steward St. Elizabeth's
Brighton, Massachusetts, 02135
United States
Dana-Farber Cancer Instiute Merrimack Valley
Methuen, Massachusetts, 01844
United States
Dana-Farber Cancer Institute South Shore
South Weymouth, Massachusetts, 02190
United States

Collaborators and Investigators

Sponsor: Dana-Farber Cancer Institute

  • Narjust Florez, MD, PRINCIPAL_INVESTIGATOR, Dana-Farber Cancer Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-04-01
Study Completion Date2027-12-01

Study Record Updates

Study Start Date2025-04-01
Study Completion Date2027-12-01

Terms related to this study

Keywords Provided by Researchers

  • Lung Cancer
  • EGFR Gene Mutation
  • EGFR-related lung cancer
  • EGFR positive lung cancer

Additional Relevant MeSH Terms

  • Lung Cancer
  • EGFR Gene Mutation